title: [Possibilities of improvement of prognosis in patients with type 2 diabetes mellitus after coronary interventions].
abstract: We present results of investigation of fenofibrate in patients with ischemic heart disease and type 2 diabetes mellitus after myocardial revascularization at various terms of its administration. We have shown its efficacy in correction of diabetic dyslipidemia, positive influence on clinical status and long term result of coronary intervention. We have established that early (first 7 days) prescription of fenofibrate - Tricor to patients with ischemic heart disease and type 2 diabetes mellitus after myocardial revascularization lowers number of diagnostic coronary angiograms and repeat percutaneous coronary interventions by 11% during first year of follow-up.
authors: N P
authors: NP
authors: Liamina
authors: É S
authors: ÉS
authors: Karpova
authors: E V
authors: EV
authors: Kotel'nikova
authors: A N
authors: AN
authors: Nosenko
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D050171:Dyslipidemias / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D009204:Myocardial Revascularization / Q000379:methods*; D011379:Prognosis; D012086:Reoperation; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000960:Hypolipidemic Agents; D011345:Fenofibrate